HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.
Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al.· Cell Reports Medicine· 0 citations
The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.
HSPC-engineered allogeneic CAR-NKT cells are established as a promising, scalable, and safer immunotherapy platform for MS, supporting their advancement toward clinical translation.
Highlights from the 2026 American Association for Cancer Research Annual Meeting demonstrate significant advances in ADC design, including dual- and multi-payload constructs, multispecific targeting strategies, and immunostimulatory payloads, with the potential to improve clinical outcomes across diverse cancer types.
